Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Equity (2020 - 2025)

Gain Therapeutics has reported Return on Equity over the past 6 years, most recently at 4.04% for Q3 2025.

  • Quarterly results put Return on Equity at 4.04% for Q3 2025, down 197.0% from a year ago — trailing twelve months through Sep 2025 was 4.04% (down 197.0% YoY), and the annual figure for FY2024 was 2.05%, down 63.0%.
  • Return on Equity for Q3 2025 was 4.04% at Gain Therapeutics, down from 3.92% in the prior quarter.
  • Over the last five years, Return on Equity for GANX hit a ceiling of 0.01% in Q4 2022 and a floor of 4.04% in Q3 2025.
  • Median Return on Equity over the past 5 years was 0.4% (2022), compared with a mean of 1.32%.
  • Biggest five-year swings in Return on Equity: grew 30bps in 2021 and later tumbled -222bps in 2023.
  • Gain Therapeutics' Return on Equity stood at 0.21% in 2021, then skyrocketed by 94bps to 0.01% in 2022, then plummeted by -18557bps to 2.24% in 2023, then dropped by -12bps to 2.51% in 2024, then crashed by -61bps to 4.04% in 2025.
  • The last three reported values for Return on Equity were 4.04% (Q3 2025), 3.92% (Q2 2025), and 3.19% (Q1 2025) per Business Quant data.